Following Syntimmune buyout, Alexion antes up $25M to double down on anti-FcRn pathway
Last September, Alexion wagered $1.2 billion — $400 million of it upfront — on little biotech Syntimmune to get its hands on a drug targeting IgG …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
